Antibodies, Monoclonal, Humanized

Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
DrugDrug NameDrug Description
DB00002CetuximabAn endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck.
DB00043OmalizumabA monoclonal anti-immunoglobulin E antibody used in the treatment of severe asthma and chronic idiopathic urticaria.
DB00051AdalimumabA monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
DB00072TrastuzumabA monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers.
DB00108NatalizumabA monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis.
DB00110PalivizumabA monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients.
DB00112BevacizumabA monoclonal anti-vascular endothelial growth factor antibody used in the treatment of many cancer types in combination with other antineoplastics.
DB01270RanibizumabA recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
DB05679UstekinumabA targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis.
DB06643DenosumabA RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures.
DB08904Certolizumab pegolA tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis.
DB09035NivolumabA PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
DB06186IpilimumabA human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.
DB09264IdarucizumabAn antibody that binds dabigatran for the reversal of anticoagulant effects of dabigatran.
DB11595AtezolizumabA monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.
DB11988OcrelizumabA CD20 specific monoclonal antibody used to treat relapsing remitting multiple sclerosis.
DB14597LanadelumabA plasma kallikrein inhibitor used to treat attacks of hereditary angioedema.
DB14042GalcanezumabA calcitonin-gene related peptide antagonist used to prevent migraines and treat cluster headaches.
DB11580RavulizumabA monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria.
DB14762RisankizumabAn interleukin-23 antagonist used to treat moderate to severe plaque psoriasis.
DB00054AbciximabA monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention.
DB00074BasiliximabA monoclonal anti-C25 antibody (interleukin-2 receptor alpha subunit) used as immunosuppressive therapy in kidney transplant patients.
DB00087AlemtuzumabA monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis.
DB00111DaclizumabA monoclonal anti-CD25 antibody that blocks the interleukin-2 receptor which is used to treat relapsing forms of multiple sclerosis.
DB01269PanitumumabA recombinant humanized monoclonal antibody used to treat EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
DB05773Trastuzumab emtansineAn antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer.
DB14907Bevacizumab zirconium Zr-89Bevacizumab zirconium Zr-89 is under investigation in clinical trial NCT01338090 (89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors).
DB15271CrizanlizumabA monoclonal antibody that targets selectin to reduce the frequency of vasooclusive crises in patients with sickle cell disease.
DB13007Enfortumab vedotinAn antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer.
DrugDrug NameTargetType
DB00002CetuximabEpidermal growth factor receptortarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00002CetuximabComplement C1r subcomponenttarget
DB00002CetuximabComplement C1q subcomponent subunit Atarget
DB00002CetuximabComplement C1q subcomponent subunit Btarget
DB00002CetuximabComplement C1q subcomponent subunit Ctarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00002CetuximabComplement C1s subcomponenttarget
DB00002CetuximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00043OmalizumabHigh affinity immunoglobulin epsilon receptor subunit alphatarget
DB00043OmalizumabHigh affinity immunoglobulin epsilon receptor subunit betatarget
DB00051AdalimumabTumor necrosis factortarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00072TrastuzumabComplement C1r subcomponenttarget
DB00072TrastuzumabComplement C1q subcomponent subunit Atarget
DB00072TrastuzumabComplement C1q subcomponent subunit Btarget
DB00072TrastuzumabComplement C1q subcomponent subunit Ctarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00072TrastuzumabComplement C1s subcomponenttarget
DB00072TrastuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00072TrastuzumabReceptor tyrosine-protein kinase erbB-2target
DB00072TrastuzumabEpidermal growth factor receptortarget
DB00108NatalizumabIntegrin alpha-4target
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00108NatalizumabComplement C1r subcomponenttarget
DB00108NatalizumabComplement C1q subcomponent subunit Atarget
DB00108NatalizumabComplement C1q subcomponent subunit Btarget
DB00108NatalizumabComplement C1q subcomponent subunit Ctarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00108NatalizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00108NatalizumabIntercellular adhesion molecule 1target
DB00110PalivizumabFusion glycoprotein F0target
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00110PalivizumabComplement C1r subcomponenttarget
DB00110PalivizumabComplement C1q subcomponent subunit Atarget
DB00110PalivizumabComplement C1q subcomponent subunit Btarget
DB00110PalivizumabComplement C1q subcomponent subunit Ctarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00110PalivizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00112BevacizumabComplement C1r subcomponenttarget
DB00112BevacizumabComplement C1q subcomponent subunit Atarget
DB00112BevacizumabComplement C1q subcomponent subunit Btarget
DB00112BevacizumabComplement C1q subcomponent subunit Ctarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00112BevacizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00112BevacizumabVascular endothelial growth factor Atarget
DB01270RanibizumabVascular endothelial growth factor Atarget
DB05679UstekinumabInterleukin-12 subunit betatarget
DB05679UstekinumabInterleukin-23target
DB06643DenosumabTumor necrosis factor ligand superfamily member 11target
DB08904Certolizumab pegolTumor necrosis factortarget
DB08904Certolizumab pegolAlcohol dehydrogenase [NADP(+)]enzyme
DB09035NivolumabProgrammed cell death protein 1target
DB06186IpilimumabCytotoxic T-lymphocyte protein 4target
DB11595AtezolizumabProgrammed cell death 1 ligand 1target
DB11988OcrelizumabB-lymphocyte antigen CD20target
DB14597LanadelumabPlasma kallikreintarget
DB14042GalcanezumabCalcitonin gene-related peptide 1target
DB14042GalcanezumabCalcitonin gene-related peptide 2target
DB11580RavulizumabComplement C5target
DB14762RisankizumabInterleukin-23target
DB00054AbciximabIntegrin beta-3target
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00054AbciximabComplement C1r subcomponenttarget
DB00054AbciximabComplement C1q subcomponent subunit Atarget
DB00054AbciximabComplement C1q subcomponent subunit Btarget
DB00054AbciximabComplement C1q subcomponent subunit Ctarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00054AbciximabComplement C1s subcomponenttarget
DB00054AbciximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00054AbciximabIntegrin alpha-IIbtarget
DB00054AbciximabVitronectintarget
DB00074BasiliximabInterleukin-2 receptor subunit alphatarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00074BasiliximabComplement C1r subcomponenttarget
DB00074BasiliximabComplement C1q subcomponent subunit Atarget
DB00074BasiliximabComplement C1q subcomponent subunit Btarget
DB00074BasiliximabComplement C1q subcomponent subunit Ctarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00074BasiliximabComplement C1s subcomponenttarget
DB00074BasiliximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00074BasiliximabInterleukin-2 receptor subunit betatarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00087AlemtuzumabCAMPATH-1 antigentarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00087AlemtuzumabComplement C1r subcomponenttarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Atarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Btarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Ctarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00087AlemtuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00111DaclizumabInterleukin-2 receptor subunit alphatarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00111DaclizumabComplement C1r subcomponenttarget
DB00111DaclizumabComplement C1q subcomponent subunit Atarget
DB00111DaclizumabComplement C1q subcomponent subunit Btarget
DB00111DaclizumabComplement C1q subcomponent subunit Ctarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00111DaclizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00111DaclizumabInterleukin-2 receptor subunit betatarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB01269PanitumumabEpidermal growth factor receptortarget
DB05773Trastuzumab emtansineReceptor tyrosine-protein kinase erbB-2target
DB05773Trastuzumab emtansineP-glycoprotein 1transporter
DB05773Trastuzumab emtansineCytochrome P450 3A4enzyme
DB05773Trastuzumab emtansineCytochrome P450 3A5enzyme
DB15271CrizanlizumabP-selectintarget
DB13007Enfortumab vedotinCytochrome P450 3A4enzyme
DB13007Enfortumab vedotinNectin-4target
DB13007Enfortumab vedotinP-glycoprotein 1transporter